FOSUN HEALTH Logo

Endometrial Cancer Treatment

catalogue

Endometrial Cancer Treatment

Endometrial Cancer Treatment

Endometrial cancer treatment has a simple shape: the uterus is removed in almost every case where cure is the aim, and everything else — node assessment, radiotherapy, chemotherapy, immunotherapy, hormone therapy — is decided by stage plus the molecular class that FIGO 2023 now counts. For most women the treatment is shorter than they fear, and for early disease it is often surgery alone.

The plan by stage

Endometrial cancer is unusual in how linear its treatment logic is. The uterus comes out in almost every curative case; the question is what travels with it and what follows it:

Situation Backbone What is added
Stage IA, low grade, no risk features Hysterectomy + tubes and ovaries, minimally invasive Nothing but follow-up in most cases
Stage IA–IB, higher grade or risk features The same operation Vaginal brachytherapy, decided by molecular class
Stage II Hysterectomy with nodal assessment External-beam radiotherapy commonly added
Stage III Surgery where complete removal is achievable Carboplatin + paclitaxel, often with radiotherapy
Stage IVA–IVB Systemic therapy first Immunotherapy for MMR-deficient tumours; pembrolizumab + lenvatinib otherwise; surgery or radiotherapy for symptom control
POLE-mutated, any stage Standard surgery Often de-escalated — the molecular class argues for less, not more

The table carries one caveat that defines modern practice: the molecular class can move a tumour across rows. A p53-abnormal stage IA is treated as if it were further along; a POLE-mutated stage III may need less than its anatomy suggests. That is why the tests belong before the plan, not after it.

The operation

The standard operation for endometrial cancer is a total hysterectomy with bilateral salpingo-oophorectomy — removal of the uterus, cervix, both fallopian tubes and both ovaries. It is more extensive than a hysterectomy done for fibroids because the tubes and ovaries are potential sites of silent spread, and leaving them would compromise staging. For apparent early-stage disease, the operation is done laparoscopically or robotically through keyhole incisions: randomised evidence and routine practice agree that recovery is faster, hospital stay shorter and wound complications fewer than with open surgery, with no trade-off in completeness.

Three practical notes matter to patients. First, the uterus is sent to pathology whole, and the final report — depth of invasion, grade, molecular class on the specimen — finalises the staging that the pre-operative MRI estimated. Second, serous and clear-cell tumours are staged like ovarian cancer, with peritoneal washing and biopsies added. Third, for the great majority of women this is a two-to-four-day hospital stay and roughly a month of ordinary recovery; the minimally invasive approach is the reason the operation feels smaller than its name suggests.

Sentinel node mapping

For decades, staging endometrial cancer meant removing most of the pelvic lymph nodes — a thorough but heavy procedure whose main legacy was leg swelling in a subset of women. Sentinel node mapping has changed that. Dye and a radioactive or fluorescent tracer are injected into the cervix, the first draining nodes light up, and only those few are removed and examined. The logic: if the first nodes are clear, disease has not travelled; if they are positive, the plan changes — and the full dissection can be reserved for the cases where it adds information.

Mapping is standard for most intermediate- and higher-risk tumours today, and for the lowest-risk disease nodes are often left untouched entirely. It is one of the clearest examples of treatment getting lighter without getting less complete — and one of the questions worth asking at any centre: is mapping part of your standard operation, or is a full dissection still the default?

Radiotherapy after surgery

Radiotherapy after surgery lowers the risk of the disease returning in the vagina and pelvis, and modern practice gives it narrowly. Vaginal brachytherapy — a short applicator delivering radiation directly to the vaginal vault over a few sessions — is the standard add-on for intermediate-risk disease; it is targeted, quick, and spares the bowel almost entirely. External-beam radiotherapy to the pelvis is reserved for higher-risk situations: deep invasion, cervical involvement, serous or clear-cell type, or involved nodes.

The molecular class weighs in here as well. POLE-mutated tumours often skip radiotherapy altogether; p53-abnormal tumours move toward external beam and combination treatment; NSMP tumours with intermediate features sit in the range where brachytherapy alone is considered. The decision is made after the final pathology, at the post-operative MDT — which is why the operation and the discussion belong in the same institution where possible.

Chemotherapy and immunotherapy

Systemic treatment enters the plan at stage III and beyond, and in recurrent disease:

  • Carboplatin + paclitaxel — the standard chemotherapy combination, given every three weeks for around six cycles; tolerable in the majority, with hair loss the main constant.
  • Immune checkpoint inhibitors for MMR-deficient tumours — where the mismatch-repair proteins are lost, PD-1 inhibitors (dostarlimab or pembrolizumab) produce durable responses in a substantial share of advanced and recurrent cases; this is the clearest immunotherapy story in gynaecological oncology.
  • Pembrolizumab + lenvatinib — for tumours without mismatch-repair deficiency, the combination is the standard immunotherapy route in advanced disease.
  • Hormone therapy — progestins and aromatase inhibitors, covered in the next section, for slow-moving hormone-sensitive disease.

The ordering matters: for advanced disease, chemotherapy usually comes first with immunotherapy added or following it, decided by the molecular class — one more reason the tests should be complete before the first cycle is given.

Hormone therapy

Because most endometrial cancers grew under estrogen, hormones that oppose estrogen can shrink them. Progestins — given as tablets or via an intrauterine device — and aromatase inhibitors, which shut down estrogen production in fat and muscle, are used in two distinct situations:

  • As definitive treatment where surgery is not possible — older women or those unfit for anaesthesia can be treated with hormone therapy alone for years, with the lining monitored by ultrasound and periodic biopsy.
  • As treatment for recurrent or metastatic disease — for low-grade, hormone-sensitive tumours, hormone therapy controls disease with far fewer side effects than chemotherapy.

Hormone therapy is slow medicine: responses build over months rather than weeks, and it suits indolent disease rather than aggressive types — serous and p53-abnormal tumours are not candidates. Within those limits, it is among the gentlest effective treatments in oncology.

Keeping the uterus

For young women who have not finished their families, a defined pathway exists — and it is narrow on purpose. The criteria: a low-grade (G1) endometrioid tumour that appears confined to the lining on MRI, no involvement beyond it, and a patient able to commit to progestin therapy with hysteroscopy every three months. The treatment is usually an intrauterine progestin device combined with oral hormones; the surveillance verifies that the lining reverts, and pregnancy is attempted — often with fertility assistance — once the response is confirmed.

Two honest caveats frame it. Response takes six to twelve months and is not guaranteed, and the uterus, having once produced a premalignant lining, remains under lifelong watch — after childbearing is complete, hysterectomy is generally advised. But within its boundaries the pathway is real and well described, and it is one of the reasons the molecular tests and MRI should be complete before any hysterectomy date is booked in a young patient.

How the decision is made

Endometrial cancer decisions sit at the junction of four specialties — gynaecological oncology, radiation oncology, medical oncology and pathology — and the correct plan is the one the whole table signs. Our MDT reviews each file against the same grid: stage by MRI, grade and type by pathology, molecular class, the patient's age, weight, fertility wishes and fitness for anaesthesia. The output is a written plan that names the operation, states whether nodes will be mapped, and pre-decides the adjuvant question under each plausible pathology result — so that the post-operative discussion is confirmation, not improvisation.

For international patients the MDT works on records alone: the ultrasound, biopsy pathology, molecular results where done (or the tissue where not), MRI and any operation note. The written assessment returns within 48 hours of the file being complete — including, where the molecular tests are missing, whether running them would change the plan, which it frequently does.

Frequently Asked Questions

Will I need chemotherapy after surgery?

Usually not for early disease. Stage IA low-grade tumours typically need nothing beyond follow-up; radiotherapy, when indicated at stage IB–II, is often brachytherapy alone. Chemotherapy enters the picture at stage III and beyond, or for aggressive types such as serous and clear-cell carcinoma. The molecular class shifts the line — a POLE-mutated tumour often avoids chemotherapy even at high stage, while a p53-abnormal one may receive it earlier — which is why the tests are done before the question is asked rather than after.

How long is the hospital stay for the operation?

For a minimally invasive hysterectomy with sentinel node mapping, most patients stay two to four nights and walk the same evening. Recovery to ordinary activity takes roughly four weeks; lifting restrictions apply for the first two. Open surgery — needed occasionally for advanced disease — adds a few days in hospital and a slower first month. The approach is chosen on imaging before the date is set, so the expected stay is known in advance, not discovered after.

What happens to hormone replacement therapy after treatment?

It depends on what was removed and why the therapy was started. With both ovaries removed, menopausal symptoms arrive abruptly and are real; short-term hormone therapy after endometrial cancer is discussed openly in modern practice, particularly after low-grade early disease, but the decision is individual and made with the oncologist rather than assumed either way. Non-hormonal alternatives for hot flushes and sleep disturbance exist and are often the first line.

Is robotic surgery better than standard keyhole surgery?

Both are established, and the evidence does not crown either: recovery, completeness and complication rates are comparable in experienced hands. Robotic platforms offer finer instrument articulation, which matters in specific situations — larger patients, adhesions, extended node dissection. What predicts the outcome is the volume of the surgeon and the team, not the brand of the platform; a high-volume laparoscopic service outperforms a low-volume robotic one. Ask about volume first and technology second.

Get the route confirmed before you travel

Choosing where to have surgery is a staging and molecular decision. Upload the biopsy, MRI and any molecular results, and our gynaecological oncology MDT will state the appropriate route and whether fertility preservation applies — in writing, within 48 hours.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*